Holen Sie sich die Stockscreener-App
66.56
0.46%
-0.31
Handel nachbörslich:
66.56
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ALC?
Forum
Prognose
Dividendenhistorie
Schlusskurs vom Vortag:
$66.87
Offen:
$66.67
24-Stunden-Volumen:
2.81M
Relative Volume:
1.38
Marktkapitalisierung:
$32.46B
Einnahmen:
$10.63B
Nettoeinkommen (Verlust:
$819.00M
KGV:
40.15
EPS:
1.6577
Netto-Cashflow:
$1.59B
1W Leistung:
-0.39%
1M Leistung:
+0.68%
6M Leistung:
-17.44%
1J Leistung:
-23.54%
1-Tages-Spanne:
$66.42
$67.03
1-Wochen-Bereich:
$65.99
$69.75
52-Wochen-Spanne:
$61.84
$92.55
Alcon Inc Stock (ALC) Company Profile
Compare ALC vs ISRG, BDX, MDLN, RMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALC
Alcon Inc
|
66.56 | 32.61B | 10.63B | 819.00M | 1.59B | 1.6577 |
ISRG
Intuitive Surgical Inc
|
415.10 | 151.33B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
150.56 | 43.07B | 21.37B | 1.41B | 3.07B | 3.9437 |
MDLN
Medline Inc
|
40.30 | 36.37B | 29.14B | 1.07B | 1.05B | 1.1956 |
RMD
Resmed Inc
|
205.84 | 31.88B | 5.54B | 1.52B | 1.74B | 10.37 |
Alcon Inc Stock (ALC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-26 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2026-01-30 | Eingeleitet | William Blair | Mkt Perform |
| 2026-01-20 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2026-01-09 | Herabstufung | Stifel | Buy → Hold |
| 2025-12-11 | Herabstufung | BofA Securities | Buy → Underperform |
| 2025-08-21 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-05-20 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2025-05-14 | Bestätigt | BTIG Research | Buy |
| 2025-03-28 | Bestätigt | Needham | Buy |
| 2025-03-25 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-01-24 | Bestätigt | Needham | Buy |
| 2025-01-10 | Hochstufung | Redburn Atlantic | Neutral → Buy |
| 2024-12-17 | Bestätigt | Needham | Buy |
| 2024-11-12 | Bestätigt | Needham | Buy |
| 2024-10-10 | Hochstufung | Redburn Atlantic | Sell → Neutral |
| 2024-09-10 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-07-15 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2024-05-15 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-04-10 | Eingeleitet | Goldman | Buy |
| 2024-03-14 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2024-02-06 | Fortgesetzt | KeyBanc Capital Markets | Overweight |
| 2024-01-23 | Eingeleitet | Bernstein | Outperform |
| 2023-12-18 | Herabstufung | Redburn Atlantic | Neutral → Sell |
| 2023-12-12 | Eingeleitet | Stifel | Buy |
| 2023-12-04 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2023-08-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-05-10 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2023-03-01 | Hochstufung | Societe Generale | Sell → Hold |
| 2022-12-22 | Eingeleitet | Mizuho | Buy |
| 2022-11-17 | Herabstufung | Societe Generale | Hold → Sell |
| 2022-08-11 | Herabstufung | Societe Generale | Buy → Hold |
| 2022-05-13 | Fortgesetzt | Credit Suisse | Outperform |
| 2022-05-12 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2022-04-08 | Eingeleitet | Needham | Buy |
| 2022-03-11 | Eingeleitet | BofA Securities | Buy |
| 2022-01-18 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2022-01-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-10-01 | Eingeleitet | Oppenheimer | Perform |
| 2021-07-14 | Eingeleitet | Deutsche Bank | Buy |
| 2021-05-06 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-03-22 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-11-12 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-07-06 | Herabstufung | Citigroup | Neutral → Sell |
| 2020-07-06 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2020-06-16 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-04-08 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-03-26 | Hochstufung | Argus | Hold → Buy |
| 2020-03-24 | Hochstufung | Societe Generale | Sell → Hold |
| 2020-03-13 | Hochstufung | UBS | Neutral → Buy |
| 2020-03-05 | Eingeleitet | Citigroup | Neutral |
| 2020-02-26 | Hochstufung | Berenberg | Hold → Buy |
| 2020-01-08 | Eingeleitet | Argus | Hold |
| 2019-10-29 | Eingeleitet | Stephens | Equal-Weight |
| 2019-08-21 | Bestätigt | BofA/Merrill | Neutral |
| 2019-06-24 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2019-06-14 | Eingeleitet | BTIG Research | Neutral |
| 2019-05-10 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-05-02 | Eingeleitet | Credit Suisse | Outperform |
Alle ansehen
Alcon Inc Aktie (ALC) Neueste Nachrichten
Can Alcon Inc. (ALC) Stock Rebound as New Eye Care Products Approach Regulatory Milestones? - Insider Monkey
Alcon Inc focuses on eye care growth and global expansion - AD HOC NEWS
Systane Complete by Alcondry eye relief with lipid layer support - AD HOC NEWS
Alcon focuses on eye-care growth as global demand for vision treatments expands - AD HOC NEWS
RxSight: Alcon Deal Reshapes The Long-Term Growth Story (NASDAQ:RXST) - Seeking Alpha
Alcon and RxSight Announce Collaboration to Develop Adjustable PCIOLs - InvisionMag.com
Alcon collaborates with RxSight to develop adjustable PCIOLs - MSN
Alcon and RxSight partner to to develop light-adjustable PCIOLs - Eyes On Eyecare
Alcon focuses on global eye care growth as a diversified medical device leader - AD HOC NEWS
RXST: Collaboration with Alcon and product innovation offset Q2 headwinds, supporting revised 2026 outlook - TradingView
Alcon, RxSight Begin Co-Developing Presbyopia-Correcting IOLs - Medical Product Outsourcing
DAILIES TOTAL1 from Alcon Inc.daily lenses engineered for all?day comfort - AD HOC NEWS
Stifel reiterates Hold on RxSight stock, $8 target on Alcon deal By Investing.com - Investing.com Nigeria
Alcon focuses on eye care growth as a global leader - AD HOC NEWS
Alcon spends up to $200m to co-develop customisable cataract lenses with RxSight - Yahoo Finance
Alcon focuses on eye care growth as demand for vision treatments rises - AD HOC NEWS
Alcon focuses on eye care growth as investors watch long-term trends - AD HOC NEWS
Alcon, RxSight Partner to Develop Adjustable Presbyopia-Correcting IOLs - VisionMonday.com
Alcon Silver Announces Shareholder Approval of Arrangement - Yahoo Finance
Alcon (ALC) Partners with RxSight for Innovative Lens Developmen - GuruFocus
Alcon, RxSight partner on adjustable lens technology By Investing.com - Investing.com South Africa
ALCON AGRXSIGHT TO RECEIVE $60 MLN UPFRONT PAYMENT UNDER AGREEMENT - Moomoo
RxSight, Inc. Announces Preliminary Second Quarter Financial Results and Product Pipeline Updates Following Strategic Collaboration Agreement - The Manila Times
Alcon and RxSight team up to develop light-adjustable cataract lenses - StreetInsider
Alcon–RxSight (NASDAQ: RXST) deal adds $60M upfront plus milestones, royalties - Stock Titan
Alcon and RxSight team up on adjustable lenses after cataract surgery - Stock Titan
Alcon focuses on eye care growth as investors watch long-term strategy - AD HOC NEWS
Price to sales forward of Alcon AG – SIX:ALC - TradingView
Alcon stock tracks its core eye care business. Investors await fresh cues. - AD HOC NEWS
Alcon Inc. (ALC) Stock Analysis: Eyeing A 26% Upside With Solid Buy Ratings - DirectorsTalk Interviews
Alcon focuses on ophthalmic growth as investor interest builds - AD HOC NEWS
Alcon stock holds its footing. Focus turns to the eye-care model. - AD HOC NEWS
Harding Loevner International Equity Portfolio's Alcon Inc(ALC) Holding History - GuruFocus
Alcon Inc (ALC) Stock Up 4.2% and Still Undervalued -- GF Score: 71/100 - GuruFocus
SYSTANE Ultra from Alcon Inc.Dry eye relief built for digital days - AD HOC NEWS
Alcon Inc focuses on eye-care growth as global demand for vision treatment expands - AD HOC NEWS
DAILIES TOTAL1 contact lenses from Alcon Inc.daily disposables built for long screen days - AD HOC NEWS
Enterprise value to revenue forward of Alcon AG – VIE:ALC - TradingView
Total30 contact lenses from Alcon Inc.monthly comfort with water gradient tech - AD HOC NEWS
ALCAlcon Inc Latest SEC Filings - Finviz
Alcon consensus holds steady, shares in focus on SIX Swiss Exchange - AD HOC NEWS
Systane class action claims eye drops falsely advertised as preservative-free - Class Action Lawsuits
MiniMed adds Alcon CEO and Medtronic executive to board By Investing.com - Investing.com Canada
Press Release: MiniMed Appoints Alcon CEO David Endicott and Linnea Burman to Its Board of Directors - Moomoo
Alcon opens the week with a full earnings calendar, shares steady ahead of next update - AD HOC NEWS
Top Intraocular Lens Market Companies Driving Innovation - SNS Insider
Alcon Inc. (ALC) Stock Analysis: A Healthcare Giant With A 29.68% Upside Potential - DirectorsTalk Interviews
Alcon highlights surgical portfolio ahead of Q2, shares trade steadily on SIX - AD HOC NEWS
MiniMed appoints Alcon CEO David Endicott and Linnea Burman to its Board of Directors - PR Newswire
Alcon adjusts capital structure, shares supported by steady eye care demand - AD HOC NEWS
Lensar Stock Slumps After Hours On Ending Merger Deal With Alcon Over FTC Pushback - Stocktwits
Finanzdaten der Alcon Inc-Aktie (ALC)
Umsatz
Nettogewinn
Free Cashflow
ENV
6.30%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):